Pages that link to "Q34336896"

The following pages link to Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. (Q34336896):

Displaying 100 items.

• Rhythmic binding of Topoisomerase I impacts on the transcription of Bmal1 and circadian period (Q24297026) (← links)
• SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage (Q24682811) (← links)
• Inhibition of Human Immunodeficiency Virus (HTV-1) Replication In Vitro by Noncytotoxic Doses of Camptothecin, a Topoisomerase I Inhibitor (Q28323784) (← links)
• Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I (Q28378884) (← links)
• Biological Mechanism Profiling Using an Annotated Compound Library (Q33193573) (← links)
• Clinical studies of camptothecin and derivatives (Q33194418) (← links)
• Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer (Q33341045) (← links)
• The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor (Q33500497) (← links)
• DNA topoisomerase-targeting antitumor drugs can be studied in yeast (Q33654182) (← links)
• Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors (Q33662415) (← links)
• Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. (Q33677099) (← links)
• Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents (Q33833531) (← links)
• Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. (Q33856425) (← links)
• Topostin, a novel inhibitor of mammalian DNA topoisomerase I from Flexibacter topostinus sp. nov. II. Purification and some properties of topostin (Q33894566) (← links)
• Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. (Q33923420) (← links)
• The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives (Q33925798) (← links)
• Identification of a topoisomerase I mutant, scsA1, as an extragenic suppressor of a mutation in scaA(NBS1), the apparent homolog of human nibrin in Aspergillus nidulans. (Q34617988) (← links)
• Transcription-dependent degradation of topoisomerase I-DNA covalent complexes (Q34784817) (← links)
• Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. (Q34967081) (← links)
• Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin (Q35020099) (← links)
• Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones (Q35072982) (← links)
• A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group (Q36114656) (← links)
• In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin (Q36116478) (← links)
• Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line (Q36292082) (← links)
• Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation (Q36293009) (← links)
• Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development (Q36431807) (← links)
• Multi-Drug Resistance Genes in the Management of Neoplastic Disease (Q36529269) (← links)
• Resistance to inhibitors of DNA topoisomerases (Q36546741) (← links)
• Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer (Q36619185) (← links)
• Inhibition of retrovirus-induced disease in mice by camptothecin. (Q36648965) (← links)
• Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy (Q36703149) (← links)
• Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks (Q36792502) (← links)
• The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells (Q36797222) (← links)
• Topoisomerase I is preferentially associated with isolated replicating simian virus 40 molecules after treatment of infected cells with camptothecin (Q36872974) (← links)
• 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents (Q37323423) (← links)
• Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents (Q37363590) (← links)
• 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents (Q37363598) (← links)
• Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide (Q37396799) (← links)
• New natural products in cancer chemotherapy (Q37608749) (← links)
• Macrocyclic pyridyl polyoxazoles: structure-activity studies of the aminoalkyl side-chain on G-quadruplex stabilization and cytotoxic activity. (Q37630342) (← links)
• Topoisomerases, new targets in cancer chemotherapy (Q37877829) (← links)
• A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay (Q38318734) (← links)
• Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin (Q38350593) (← links)
• Biochemical changes in testicular varicocele (Q38666261) (← links)
• Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I. (Q39171279) (← links)
• Topoisomerase I inhibitors and drug resistance (Q40028536) (← links)
• Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan (Q40066258) (← links)
• Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination (Q40156233) (← links)
• Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics. (Q40308617) (← links)
• Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells (Q40514331) (← links)
• Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites (Q40530650) (← links)
• Topoisomerase I in multiple drug resistance (Q40534060) (← links)
• Cellular resistance to cancer chemotherapy. (Q40596146) (← links)
• Antineoplastic drug resistance and breast cancer (Q40619705) (← links)
• Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors (Q40630446) (← links)
• Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells (Q40658370) (← links)
• 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials (Q40694325) (← links)
• Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs (Q40853121) (← links)
• Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma (Q40876335) (← links)
• Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates (Q40902571) (← links)
• Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance (Q40966942) (← links)
• DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant (Q41094672) (← links)
• Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential (Q41099255) (← links)
• Cellular resistance to camptothecins (Q41307850) (← links)
• Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks (Q41307860) (← links)
• Topoisomerases in human leukemia. (Q41315133) (← links)
• Drug resistance mechanisms of topoisomerase I drugs. (Q41315175) (← links)
• Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan (Q41317523) (← links)
• Two subforms of eukaryotic topoisomerase I. Purification and structure-function relationships (Q41589200) (← links)
• Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo (Q42213264) (← links)
• Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines (Q42279792) (← links)
• Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells (Q42685776) (← links)
• Current perspectives on camptothecins in cancer treatment (Q42715927) (← links)
• Inhibition of Moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors (Q42800695) (← links)
• Drug-induced loss of unstably amplified genes (Q43492654) (← links)
• Testosterone Dependent Regulation of the Enzymes involved in DNA Synthesis in the Rat Ventral Prostate (Q43544691) (← links)
• Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats (Q44196282) (← links)
• Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I. (Q44220157) (← links)
• Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. (Q44473090) (← links)
• Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives (Q44574358) (← links)
• Acidic phospholipids directly inhibit DNA binding of mammalian DNA topoisomerase I. (Q44649669) (← links)
• Role of DNA topoisomerase I in the replication of herpes simplex virus type 2. (Q45229473) (← links)
• Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. (Q52678451) (← links)
• Determinants of drug response in camptothecin-11-resistant glioma cell lines. (Q54187666) (← links)
• CPT-K5 (Q54814409) (← links)
• RPMI-8402 (Q54951273) (← links)
• DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. (Q54966041) (← links)
• Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. (Q55004249) (← links)
• Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. (Q55026118) (← links)
• No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. (Q55297596) (← links)
• Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine (Q61642710) (← links)
• Contribution of topoisomerase I to conversion of single-strand into double-strand DNA breaks (Q64389113) (← links)
• Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice (Q67486552) (← links)
• Clinical studies of irinotecan alone and in combination with cisplatin (Q72149455) (← links)
• UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilomyces (Q72723166) (← links)
• Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining) (Q73455009) (← links)
• Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin (Q73825740) (← links)
• Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC) (Q83964468) (← links)
• The challenge of drug resistance in cancer treatment: a current overview (Q88809961) (← links)
• Expression of circular and linearized bacterial chloramphenicol acetyltransferase genes with or without viral promoters after injection into fertilized eggs, unfertilized eggs and oocytes ofXenopus laevis (Q89561014) (← links)